Sigyn Therapeutics, Inc.
SIGY
$2.75
$0.2610.44%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.17% | 5.36% | 25.35% | 15.75% | 13.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.02% | 2.61% | 24.84% | 23.44% | 24.51% |
| Operating Income | 5.02% | -2.61% | -24.84% | -23.44% | -24.51% |
| Income Before Tax | 8.77% | 19.43% | -4.30% | -1.45% | 0.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.77% | 19.43% | -4.30% | -1.45% | 0.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.77% | 19.43% | -4.30% | -1.45% | 0.83% |
| EBIT | 5.02% | -2.61% | -24.84% | -23.44% | -24.51% |
| EBITDA | 4.88% | -2.82% | -25.17% | -23.76% | -24.73% |
| EPS Basic | 21.66% | 32.39% | 15.68% | 18.10% | 19.88% |
| Normalized Basic EPS | 31.54% | 39.53% | 13.03% | 15.29% | 7.78% |
| EPS Diluted | 21.50% | 32.16% | 15.57% | 18.39% | 21.87% |
| Normalized Diluted EPS | 31.54% | 39.53% | 13.03% | 15.29% | 7.78% |
| Average Basic Shares Outstanding | 22.19% | 21.13% | 21.82% | 23.05% | 23.87% |
| Average Diluted Shares Outstanding | 22.19% | 21.13% | 21.82% | 23.05% | 23.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |